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Abstract
Background: Increased plasma YKL-40 has been reported in Alzheimer’s disease (AD), but its levels in other
neurodegenerative diseases are unknown. Here, we aimed to investigate plasma YKL-40 in the spectrum of
neurodegenerative dementias.
Methods: YKL-40 was quantified in the plasma of 315 cases, including healthy controls (HC), neurological disease
controls (ND), AD, vascular dementia (VaD), frontotemporal dementia (FTD), sporadic Creutzfeldt-Jakob disease (CJD)
and Lewy body dementia (LBD). Diagnostic accuracy in the differential diagnostic context and influence of age and
gender was assessed.
Results: Highest YKL-40 levels were detected in CJD, followed by LBD, VaD, AD, FTD, ND and HC. YKL-40 was
associated to age but not to sex. After controlling for age, YKL-40 was significantly elevated in CJD compared to HC
(p < 0.001), ND, AD and VaD (p < 0.01) and in LBD compared to HC (p < 0.05). In CJD, YKL-40 concentrations were
significantly higher at late disease stages.
Conclusions: Plasma YKL-40 is significantly elevated in CJD regardless of clinical and genetic parameters, with
moderate diagnostic accuracy in the discrimination from control cases. Our study discards a potential use of this
biomarker in the differential diagnostic context but opens the possibility to be explored as a marker for CJD
monitoring.
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Introduction
YKL-40, also known as chitinase-3-like protein 1
(CHI3L1), is a secreted glycoprotein expressed in several
tissues and involved in activation of the innate immune
system and in cell processes in relation to extracellular
matrix remodeling [1–3]. Cerebrospinal fluid (CSF)
concentrations of YKL-40 are significantly increased in
sporadic Creutzfeldt-Jakob disease (CJD) and Alzhei-
mer’s disease (AD), while other neurodegenerative
dementias such as frontotemporal dementia (FTD),
Lewy body dementia (LBD) and vascular dementia
(VaD) show normal to slightly altered levels [4–6].
However, the potential role of YKL-40 as blood-based
biomarker in the differential diagnostic has not been
explored. In AD, plasma YKL-40 concentrations were
reported to be increased, but with limited utility as a
diagnostic marker [7] presenting moderate effect sizes
according to meta-analysis studies [8]. The levels of
plasma YKL-40 in other neurodegenerative dementias
are unknown.
Here we evaluated the accuracy of plasma YKL-40 in




Blood was collected in plasma-EDTA tubes at the
Department of Transfusion Medicine (healthy controls
(HC)) and at the Department of Neurology–Clinical
Dementia Center (neurological disease controls (ND),
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: avillar@gwdg.de; franc.llorens@gmail.com
†Franc Llorens and Inga Zerr are equal senior authors.
1Department of Neurology, Clinical Dementia Center and National Reference
Center for CJD Surveillance, University Medical School, Robert Koch 40,
37075 Göttingen, Germany
Full list of author information is available at the end of the article
Villar-Piqué et al. Journal of Neuroinflammation          (2019) 16:145 
https://doi.org/10.1186/s12974-019-1531-3
sporadic Creutzfeldt-Jakob disease (CJD), Alzheimer’s
disease (AD), frontotemporal dementia (FTD), Lewy
body dementia (LBD) and vascular dementia (VaD)) in
the Universitätsmedizin Göttingen (Germany) under
same pre-analytical conditions.
The HC group was composed of healthy blood donors
with absence of any relevant clinical finding. The ND
group was composed of cases with neurological condi-
tions not associated with neurodegenerative pathology
diagnosed according to acknowledged standard neuro-
logic clinical and para-clinical findings based on the
International Classification of Diseases 10th Edition
definitions. AD was diagnosed according to the National
Institute on Aging-Alzheimer’s Association workgroups
(NIA-AA) criteria [9]. CJD cases were classified as prob-
able or definite according to diagnostic consensus
criteria [10, 11]. The Lewy body dementia (LBD) group
included dementia with Lewy bodies (DLB) and Parkin-
son’s disease dementia (PDD) cases. The diagnosis of
DLB was based on the criteria of McKeith [12]. PDD
diagnosis was based on the task force of the Movement
Disorder Society (MDS) criteria [13]. FTLD was diag-
nosed according to the International Behavioural Variant
FTD Criteria Consortium for bvFTD [14]. VaD diagnosis
was based on clinical and radiological criteria as de-
scribed by Roman (National Institute of Neurological
and Communicative Disorders and Stroke and the
Alzheimer’s Disease and Related Disorders Association
(NINDS-AIREN)) [15]. In CJD cases, genetic testing of
the codon 129 polymorphism of prion protein gene
(PRNP) was conducted as described before [16]. For
disease stage, samples were stratified in three categories
according to whether they underwent blood uptake in
the first (early) (time of blood uptake to disease onset/
total duration of the disease < 0.33), second (middle)
(0.33–0.66), or third (last) (> 0.66) stage of the disease.
Disease duration was recorded as the time (in months)
from symptom onset to the death of the patient.
Plasma YKL-40 quantification
Plasma YKL-40 was measured with the MicroVue YKL-
40 EIA ELISA kit from Quidel following the manufac-
turer’s instructions. Samples were diluted 1:2 to 1:4.
Intra- and inter-assay coefficient of variation was 9% and
14%, respectively.
Statistical analysis
We performed one-way analysis of variance followed by
Tukey correction to compare age between disease
groups. Association between YKL-40 levels and age was
explored with Pearson correlation coefficient. We log-
transformed YKL-40 concentration to obtain a normal
distribution and applied analysis of covariance followed
by Tukey correction to assess the differences between
groups controlling for age as covariant. Association be-
tween YKL-40 and sex was investigated with the Mann-
Whitney test. Receiver operating characteristic (ROC)
curve and areas under the curve (AUC) with 95% confi-
dence intervals (95%CI) were calculated to assess diag-
nostic accuracies between diagnostic groups. All
analyses were performed using GraphPad Prism software
and multcomp package in R [17].
Results
The study population consisted of 315 plasma age-
matched cases with the exception of VaD cases that were
significantly older than HC (p < 0.01) (Table 1). In the total
population, YKL-40 was associated with age (rho = 0.21,
p < 0.001) (Fig. 1a), but not with sex (p = 0.20) (Fig. 1b).
Mean YKL-40 concentrations were higher in neurodegen-
erative dementias compared to HC (84 ng/mL) and ND
(95 ng/mL), with highest concentrations detected in CJD
(189 ng/mL), followed by LBD (167 ng/mL), VaD (140 ng/
mL), AD (133 ng/mL) and FTD (125 ng/mL) (Table 1).
After age correction, YKL-40 levels appeared significantly
higher in CJD versus HC (p < 0.001), ND, AD and VaD
(p < 0.01) and in LBD compared to HC (p < 0.05) (Fig. 1c).






YKL-40 (ng/mL) AUC (95% CI)
Mean + SD 95% CI vs. HC vs. ND
HC 70 22/48 66 ± 5 84 ± 84 63–104 0.64 (0.53–0.74)
ND 44 26/18 66 ± 12 95 ± 61 76–114 0.64 (0.53–0.74)
AD 50 25/25 69 ± 10 133 ± 110 102–164 0.62 (0.51–0.73) 0.55 (0.43–0.67)
VaD 22 8/14 72 ± 10** 140 ± 150 73–206 0.56 (0.40–0.72) 0.51 (0.34–0.68)
FTD 17 11/6 68 ± 12 125 ± 108 69–181 0.65 (0.50–0.80) 0.55 (0.38–0.73)
CJD 78 51/27 67 ± 8 189 ± 167 151–227 0.81 (0.74–0.88) 0.72 (0.63–0.81)
LBD 34 13/21 69 ± 8 167 ± 157 112–222 0.70 (0.59–0.81) 0.63 (0.49–0.76)
Number of cases (n), sex (female [f]/male [m]), age in years (mean values ± standard deviation (SD)), YKL-40 plasma concentrations (mean values ± SD) and 95%
confidence interval (95% CI)) and area under the curve (AUC) with 95% CI values for each dementia diagnostic comparison versus HC and ND are indicated
**p < 0.01
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Area under the curve (AUC) for the discrimination of
neurodegenerative dementia groups from controls ranged
from 0.56 to 0.81 for HC and from 0.51 to 0.72 for ND, in-
dicating low diagnostic value except in the discrimination
between CJD from HC, which achieved a moderate value
(0.81) (Table 1).
Since the CJD group presented the most significant
YKL-40 increase compared to other diagnostic groups,
we conducted further investigations. We stratified CJD
cases depending on the codon 129 polymorphism of
PRNP gene, but no differences in YKL-40 concentrations
were detected between methionine/methionine (MM)
(165 ng/mL, n = 49), methionine/valine (MV) (212 ng/
mL, n = 10) and valine/valine (VV) (173 ng/mL, n = 13)
cases (Fig. 2a). Similarly, no differences were detected
between the most prevalent CJD subtypes, MM1 (136
ng/mL, n = 34) and VV2 (156 ng/mL, n = 12) (p = 0.32)
(Fig. 2b). To assess the potential alteration of plasma
YKL-40 along disease progression, CJD cases were strati-
fied in three groups according to the stage of the disease
where the blood was collected (1/early: n = 13, 2/middle:
n = 16 and 3/late: n = 40 disease stage). We found a sig-
nificant increase of YKL between late disease stage (215
ng/mL) and early disease stage (104 ng/mL, p = 0.036)
(Fig. 2c). However, lack of association between YKL-40
concentrations and disease duration was present in the
CJD group (p = 0.32) (Fig. 2d).
Discussion
Many efforts are devoted to discover blood-based clin-
ical biomarkers for the diagnosis of neurodegenerative
diseases. In this search, plasma YKL-40 has been posi-
tioned as a promising candidate and a significant eleva-
tion was reported in mild AD-type dementia and early
AD compared to controls [7, 18], but the significance of
these findings in the differential diagnostic context of
neurodegenerative dementias was unknown. Although
we were able to detect increased mean plasma YKL-40
concentrations in AD compared to controls, the com-
parative analysis in different dementia conditions indi-
cated that only statistically significant alterations were
observed between LBD and HC and between CJD and
HC, ND, AD and VaD. Resultant AUC values were low
(< 0.8), except from that obtained between CJD and HC,
which reached 0.81. However, this value was still far
from that rendered by CSF YKL-40 between CJD and
neurological controls (AUC = 0.92) [4].
Plasma YKL-40 levels were influenced by age but not
by sex, as it is the case of CSF YKL-40 [7]. Within the CJD
group, no differences in YKL-40 levels were detected based
on the most prevalent clinical subtypes, MM1 and VV2,
even though they display different clinic-pathological out-
comes. Similarly, no association between plasma YKL-40
and codon 129 polymorphism of PRNP either disease dur-
ation was observed, in agreement with the data obtained for
CSF YKL-40 [4]. Thus, the moderate AUC value achieved in
the discrimination of CJD from HC presents robustness in
front of clinical heterogeneity. By contrast, we found that
CJD cases at early disease stages present significantly lower




Fig. 1 Plasma YKL-40 in the differential diagnostic context of
neurodegenerative dementia and association with demographics. a
Association between YKL-40 concentration and age at disease onset
in the study population. b YKL-40 concentration stratified by sex. c
YKL-40 concentration in HC, ND, AD, VaD, FTD, CJD and LBD. After
age correction, YKL-40 was significantly elevated in CJD compared
to HC (p < 0.001), ND, AD and VaD (p < 0.01) and in LBD compared
to HC (p < 0.05). *p < 0.05, **p < 0.01 and ***p < 0.001
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of plasma YKL-40 as diagnostic biomarker is rather limited
and our data do not support its usefulness in the differential
diagnostic context, this marker may serve in the evaluation
of disease progression and monitoring of potential thera-
peutic interventions.
Being CSF YKL-40 considered a sound marker of
neuro-inflammation, its rise in CJD, AD and other
neurodegenerative diseases characterized by neuro-
inflammatory profile is expected [4–6, 19]. However, the
weak correlation between CSF and plasma YKL-40 previ-
ously reported [7, 20] and the fact that YKL-40 levels in
blood are not altered in diagnostic groups where CSF
levels are so [20] indicates that alternative mechanisms,
other than direct CSF-blood exchange, might exist to ex-
plain the regulation of plasma YKL-40 herein observed.
In the brain, the expression of YKL-40 upon inflamma-
tion conditions is mainly attributed to reactive astrocytes
[7, 21–23]. In the case of CJD, the presence of perivascu-
lar astrocytes was detected in cortical regions [4]. Thus,
it is tempting to speculate that, upon damage of the brain
blood vessels or impairment of the blood-brain barrier,
which is common in many neurodegenerative diseases
[24], this subset of astrocytes could release brain-derived
YKL-40 in the blood. In this case, the increase of YKL-40
in plasma at advanced CJD stage that we observed may re-
flect, not only the degree of neuro-inflammation, but also
suspected damage in brain blood vessels. Further investi-
gations will be necessary to demonstrate this hypothesis
and clarify the origin of YKL-40 in the plasma of patients
with neurodegenerative dementia.
Conclusions
Altogether, our study indicates that plasma YKL-40 may
contribute to the diagnosis of CJD regardless of clinical
heterogeneity, but it should be combined with other
blood-based biomarkers to increase its diagnostic per-
formance. Contrarily, our data do not support the use of
this marker in the challenging differential diagnostic
context of neurodegenerative dementias. Additionally, a
potential use as a CJD progression marker is envisaged.
A B
C D
Fig. 2 Influence of genetic and clinical data on plasma YKL-40 concentrations in CJD patients. a YKL-40 in CJD stratified by prion protein gene (PRNP)
codon 129 polymorphism (M=methionine, V = valine). Kruskal-Wallis test followed by Dunn’s post hoc test (correction for multiple testing) was
applied. b YKL-40 in CJD MM1 and VV2 subtypes. Mann-Whitney U test was used. c YKL.40 concentrations stratified by disease stage at the time of
blood collection. Samples were grouped into three categories according to whether they underwent blood uptake in the first (< 0.33), second (0.33–
0.66), or third (> 0.66) stage of the disease. Kruskal-Wallis test followed by Dunn’s post hoc test (correction for multiple testing) was applied, *p < 0.05. d
Association between YKL-40 concentrations and disease duration (months) in CJD patients. Spearman rank correlation was used
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